RhumbLine Advisers
ANAC

RhumbLine Advisers’s ANACOR PHARMACEUTICALS INC COM ANAC Stock Holding History

RhumbLine Advisers’s Portfolio ANAC Stock Details ANAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-46,463
Closed -$2.48M – 3135
2016
Q1 		$2.48M Buy
46,463
+1,035
+2% +$76.4K 0.01% 1224
2015
Q4 		$5.13M Buy
45,428
+2,915
+7% +$321K 0.02% 810
2015
Q3 		$5M Buy
42,513
+2,621
+7% +$342K 0.02% 811
2015
Q2 		$3.09M Sell
39,892
-2,570
-6% -$168K 0.01% 1132
2015
Q1 		$2.46M Buy
42,462
+4,050
+11% +$172K 0.01% 1259
2014
Q4 		$1.24M Buy
38,412
+2,175
+6% +$65.3K ﹤0.01% 1669
2014
Q3 		$887K Sell
36,237
-700
-2% -$14.2K ﹤0.01% 1839
2014
Q2 		$655K Buy
36,937
+14,703
+66% +$237K ﹤0.01% 2097
2014
Q1 		$445K Sell
22,234
-1,200
-5% -$23.3K ﹤0.01% 2295
2013
Q4 		$393K Buy
23,434
+300
+1% +$4.15K ﹤0.01% 2403
2013
Q3 		$246K Sell
23,134
-241
-1% -$2.11K ﹤0.01% 2669
2013
Q2 		$131K Buy
+23,375
New +$142K ﹤0.01% 3176

Other funds holding ANAC

KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
CIM
CIM Investment Management Pittsburgh, Pennsylvania $375M AUM 32.03% 1-Year Est. Return

RhumbLine Advisers's ANAC Position: Q2 2016 in Review

RhumbLine Advisers sold out of ANACOR PHARMACEUTICALS INC COM (ANAC) in Q2 2016, closing a stake of 46,463 shares — an estimated $2.48M sold.

RhumbLine Advisers first reported a position in ANAC in Q2 2013 and held it in 12 quarters. The position peaked at $5.13M in Q4 2015. 2 funds tracked by Wall St. Rank hold ANAC as of Q2 2016.

  • RhumbLine Advisers reported no remaining ANACOR PHARMACEUTICALS INC COM position as of Q2 2016 after selling out during the quarter.
  • RhumbLine Advisers sold 46,463 ANACOR PHARMACEUTICALS INC COM shares in Q2 2016, an estimated $2.48M.
  • RhumbLine Advisers first reported a position in ANACOR PHARMACEUTICALS INC COM in Q2 2013 and held it in 12 quarters.
  • RhumbLine Advisers's ANACOR PHARMACEUTICALS INC COM position peaked at $5.13M in Q4 2015.
  • 2 funds tracked by Wall St. Rank held ANACOR PHARMACEUTICALS INC COM as of Q2 2016.

Based on RhumbLine Advisers's 13F filing for Q2 2016, filed 11 Aug 2016.